BƯỚC ĐẦU ĐÁNH GIÁ KẾT QUẢ ĐIỀU TRỊ TÂN HỖ TRỢ UNG THƯ VÚ GIAI ĐOẠN II–III TẠI BỆNH VIỆN ĐA KHOA TÂM ANH THÀNH PHỐ HỒ CHÍ MINH

Abstract

Objective: To evaluate the overall response rate (ORR), pathologic complete response (pCR), nodal conversion, and residual cancer burden (RCB) following neoadjuvant systemic therapy in patients with stage II–III breast cancer in real-world clinical practice.

Methods: This retrospective descriptive study included 35 patients with stage II–III breast cancer who received neoadjuvant systemic therapy followed by surgery at Tam Anh General Hospital, Ho Chi Minh City, between September 2021 and November 2025. Breast cancer subtypes were classified according to estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) status. Pathologic complete response was defined as the absence of residual invasive cancer in both the breast and regional lymph nodes after treatment (ypT0/is ypN0).

Results: The overall clinical response rate was 65.7%, including a clinical partial response (cPR) rate of 57.1% and a clinical complete response (cCR) rate of 8.6%. The overall pCR rate was 25.7%. Pathologic complete response varied substantially across biological subtypes, reaching 62.5% in triple-negative breast cancer (TNBC) and 66.7% in HER2-positive breast cancer, compared with 8.3% in hormone receptor-positive/HER2-negative disease. The nodal conversion rate was 35.5%. Treatment-related toxicities were infrequent and manageable. No cases of heart failure were observed, while grade 4 febrile neutropenia occurred in 8.6% of patients.

Conclusion: Neoadjuvant systemic therapy achieved pathological responses in patients with stage II–III breast cancer, with response rates varying across biological subtypes. Treatment-related toxicities were generally manageable.